BMS' Yeryoy and Roche's Zelboraf get final NICE nod
This article was originally published in Scrip
NICE, the health technology appraisal for for England and Wales, has published final and binding guidance recommending both Bristol-Myers Squibb's Yervoy (ipillimumab) and Roche's Zelboraf (vemurafenib) for melanoma patients. Both recommendations hinge on a confidential discount offered under a patient access scheme.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.